Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor
To the Editor: Dr Alexandersen and colleagues1 found that ipriflavone, which is available as an
over-the-counter product, was ineffective at preventing bone loss in postmenopausal
white women. We have several concerns about the study's design.
First, each of the women in the study had osteoporosis, with a bone
density T score of 0.86 or less. They were each given 500 mg/d of supplemental
calcium, which is well below the recommended dose of 1500 mg/d for women with
osteoporosis. Also, because there is a wide range of calcium absorption from
different available preparations, the specific calcium product must also be
known to ensure adequate calcium intake.
Schelonka EP, Usher A. Ipriflavone and Osteoporosis. JAMA. 2001;286(15):1836–1837. doi:https://doi.org/10.1001/jama.286.15.1833
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: